circCNN2通过ALKBH5 / YTHDF2介导的m6A调节和miR-615-5p海绵化驱动子宫内膜癌的进展
Chunyan Cai1, Xing Peng1, Yaqing Han1
1Department of Gynecology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, China.
Life sciences
|November 28, 2025
概括
循环RNA circCNN2通过调节miR-615-5p/MYH14轴驱动子宫内膜癌. 针对这种途径为子宫内膜癌提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 史诗转录组学 史诗转录组学
背景情况:
- 子宫内膜癌 (EC) 是一种流行的妇科恶性瘤.
- 循环RNAs (circRNAs) 越来越多地被认为是癌症中的角色,但它们在EC中的功能和调节仍然不完全理解.
- 经转录组的修改,如N6-甲基氨酸 (m6A),是RNA代谢和功能的关键调节者.
研究的目的:
- 阐明circCNN2在子宫内膜癌进展中的作用.
- 为了研究circCNN2.2的表皮转录学调节.
- 在EC中探索circCNN2,miR-615-5p和MYH14之间的相互作用.
主要方法:
- 定量实时PCR (qRT-PCR) 用于EC组织和细胞系中的circCNN2表达分析.
- 甲基化RNA免疫沉 (MeRIP) 来评估m6A的修饰.
- RNA下拉,双化酶记者测定和救援实验以验证分子相互作用.
- 在体外功能测试 (增殖,迁移,入侵,亡) 和体内异种移植模型.
主要成果:
- 在EC组织和细胞系中,CircCNN2显著过度表达.
- 通过ALKBH5介导的去甲基化稳定circCNN2,而YTHDF2通过m6A促进其降解.
- CircCNN2 作为 miR-615-5p 的分子海绵,从而抑制 MYH14 的下调.
- 击败circCNN2抑制了瘤生长,增殖,迁移和入侵,并诱导了亡,MYH14过度表达的效果被逆转.
- 在体内研究表明,circCNN2耗尽减少了瘤生长和转移.
结论:
- CircCNN2通过m6A调节的circRNA-miRNA-mRNA轴 (circCNN2/miR-615-5p/MYH14) 作为子宫内膜癌的致癌驱动因素.
- 这一途径是子宫内膜癌的潜在治疗标.
- 这些发现有助于理解circRNA表写体调节,并提供潜在的诊断/预后生物标志物.
更多相关视频
07:26Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
987
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
7.1K
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
MicroRNAs
3.7K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs
23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Induced Pluripotent Stem Cells
5.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.3K
